New antiinflammatory and platelet-preserving effects of aprotinin (Q34448237)

2 August 2017

1 reference

title

New antiinflammatory and platelet-preserving effects of aprotinin (English)

1 reference

2 August 2017

Landis RC

1

1 reference

2 August 2017

Haskard DO

series ordinal

2

1 reference

2 August 2017

Taylor KM

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

The Annals of Thoracic Surgery

2 August 2017

published in

1 reference

2 August 2017

volume

72

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

S1808-13

1 reference

Effect of aprotinin on need for blood transfusion after repeat open-heart surgery

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Effects of minimal-dose aprotinin on coronary artery bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

The efficacy and safety of aprotinin use in cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin and vein graft occlusion--the controversy continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

The antithrombotic and antiinflammatory mechanisms of action of aprotinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin versus lysine analogues: the debate continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Domains specifying thrombin–receptor interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

How the protease thrombin talks to cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin can inhibit the proteolytic activity of thrombin. A fluorescence and an enzymatic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

PAR3 is a cofactor for PAR4 activation by thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin administration in the pericardial cavity does not prevent platelet activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Platelet preservation during cardiopulmonary bypass with aprotinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin administration in the pericardial cavity does not prevent platelet activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Inflammatory response to cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

SIRS--the systemic inflammatory response syndrome after cardiac operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Effect of aprotinin on endothelial cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Molecular mechanisms of leukocyte recruitment in the inflammatory process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Inhibition of neutrophil L-selectin shedding: a potential anti-inflammatory effect of aprotinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Leukocyte integrin expression in patients undergoing cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Vascular protease receptors: integrating haemostasis and endothelial cell functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2903193-9

10.1016/S0003-4975(01)03193-9

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference